Published in J Neuroimmunol on November 10, 2011
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
IFN-β treatment requires B cells for efficacy in neuroautoimmunity. J Immunol (2015) 0.87
Simultaneous quantification of T-cell receptor excision circles (TRECs) and K-deleting recombination excision circles (KRECs) by real-time PCR. J Vis Exp (2014) 0.75
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens (2014) 2.03
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol (2012) 1.95
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol (2011) 1.82
Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A (2004) 1.65
T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation (2005) 1.56
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry (2013) 1.55
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension (2011) 1.54
Interferon β for secondary progressive multiple sclerosis: a systematic review. J Neurol Neurosurg Psychiatry (2012) 1.54
Endothelial nitric oxide synthase (Glu298Asp) polymorphism is an independent risk factor for migraine with aura. Headache (2006) 1.52
Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood (2004) 1.46
Structural alterations in subcutaneous small resistance arteries predict changes in the renal function of hypertensive patients. J Hypertens (2010) 1.46
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res (2003) 1.45
A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Neurology (2009) 1.45
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol (2012) 1.44
Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol (2007) 1.44
Celiac disease-related antibodies in Italian children with epilepsy. Pediatr Neurol (2009) 1.43
A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol (2009) 1.41
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol (2003) 1.39
Efficacy and specificity of intensive cognitive rehabilitation of attention and executive functions in multiple sclerosis. J Neurol Sci (2009) 1.39
Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. J Peripher Nerv Syst (2005) 1.37
Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep (2008) 1.22
Will Rogers phenomenon in multiple sclerosis. Ann Neurol (2008) 1.21
Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res (2011) 1.21
Simultaneous quantification of recent thymic T-cell and bone marrow B-cell emigrants in patients with primary immunodeficiency undergone to stem cell transplantation. Clin Immunol (2010) 1.20
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer (2009) 1.18
HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta (2011) 1.18
Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain (2006) 1.16
Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res (2006) 1.15
Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain (2011) 1.12
Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer (2005) 1.11
Type I interferon-dependent gene MxA in perinatal HIV-infected patients under antiretroviral therapy as marker for therapy failure and blood plasmacytoid dendritic cells depletion. J Transl Med (2008) 1.11
Cumulative effect of predisposing genotypes and their interaction with modifiable factors on the risk of ischemic stroke in young adults. Stroke (2005) 1.11
The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J Immunol (2010) 1.10
Corpus callosum damage and cognitive dysfunction in benign MS. Hum Brain Mapp (2009) 1.09
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A (2013) 1.08
Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation. J Lipid Res (2011) 1.08
Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer (2012) 1.08
Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev (2011) 1.07
Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. Eur J Immunol (2005) 1.07
Mesenchymal cells from human amniotic fluid survive and migrate after transplantation into adult rat brain. Cell Biol Int (2007) 1.07
Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients. Neuroimage (2005) 1.04
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev (2011) 1.04
Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol (2005) 1.04
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol (2011) 1.03
"Save 30% if you buy today". Online pharmacies and the enhancement of peripheral thinking in consumers. Pharmacoepidemiol Drug Saf (2010) 1.02
Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res (2009) 1.01
Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. Arch Neurol (2005) 1.01
Multiple sclerosis: effects of cognitive rehabilitation on structural and functional MR imaging measures--an explorative study. Radiology (2012) 1.01
Intercenter differences in diffusion tensor MRI acquisition. J Magn Reson Imaging (2010) 1.01
CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J Pain Res (2012) 1.00
Combined decrease of defined B and T cell subsets in a group of common variable immunodeficiency patients. Clin Immunol (2006) 1.00
Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. Arch Neurol (2005) 0.99
Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. Neuroimage (2008) 0.99
Sialidase NEU3 is a peripheral membrane protein localized on the cell surface and in endosomal structures. Biochem J (2007) 0.99
Cyberdrugs: a cross-sectional study of online pharmacies characteristics. Eur J Public Health (2009) 0.99
Thymic and bone marrow output in patients with common variable immunodeficiency. J Clin Immunol (2011) 0.99
Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases. Neurol Sci (2009) 0.98
Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem (2009) 0.98
Immunological patterns identifying disease course and evolution in multiple sclerosis patients. J Neuroimmunol (2005) 0.97
Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology (2009) 0.97
Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev (2012) 0.97
Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. Arch Neurol (2002) 0.96
Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology (2012) 0.96
Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. J Magn Reson Imaging (2007) 0.96
Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev (2013) 0.96
Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst (2011) 0.95
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain (2009) 0.95
Neuroactive steroids and peripheral neuropathy. Brain Res Rev (2007) 0.94
Peripheral neurotoxicity of platinum-based chemotherapy. Nat Rev Cancer (2008) 0.93
A genome-wide association study in progressive multiple sclerosis. Mult Scler (2012) 0.93
Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. Cancer Res (2010) 0.93
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. Am J Hematol (2014) 0.93
High prevalence of a variant of SENV in intravenous drug user HIV-infected patients. J Med Virol (2002) 0.93
Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. Ann Neurol (2008) 0.91
The topographical distribution of tissue injury in benign MS: a 3T multiparametric MRI study. Neuroimage (2007) 0.91
BDNF genetic variations increase the risk of Alzheimer's disease-related depression. J Alzheimers Dis (2009) 0.91
IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci (2002) 0.91
The world of e-patients: A content analysis of online social networks focusing on diseases. Telemed J E Health (2010) 0.90